AstraZeneca_NNP Annual_JJ Report_NNP and_CC Financial_NNP Statements_NNP 70_CD Form_NN 20-F_JJ Information_NN 2004_CD Preparation_NNP of_IN the_DT Financial_NNP Statements_NNP and_CC Directors_NNS Responsibilities_NNS The_DT Directors_NNS are_VBP required_VBN by_IN UK_NNP company_NN law_NN to_TO prepare_VB for_IN each_DT accounting_NN period_NN financial_JJ statements_NNS which_WDT give_VBP a_DT true_JJ and_CC fair_JJ view_NN of_IN the_DT state_NN of_IN affairs_NNS of_IN the_DT Group_NNP and_CC the_DT Company_NN as_IN at_IN the_DT end_NN of_IN the_DT accounting_NN period_NN and_CC of_IN the_DT profit_NN or_CC loss_NN for_IN that_DT period_NN ._.
In_IN preparing_VBG the_DT financial_JJ statements_NNS ,_, the_DT Directors_NNS are_VBP required_VBN to_TO select_VB suitable_JJ accounting_NN policies_NNS and_CC apply_VB them_PRP consistently_RB and_CC make_VB reasonable_JJ and_CC prudent_JJ judgements_NNS and_CC estimates_NNS ._.
Applicable_JJ accounting_NN standards_NNS also_RB have_VBP to_TO be_VB followed_VBN and_CC a_DT statement_NN made_VBD to_TO that_DT effect_NN in_IN the_DT financial_JJ statements_NNS ,_, subject_JJ to_TO any_DT material_NN departures_NNS being_VBG disclosed_VBN and_CC explained_VBN in_IN the_DT notes_NNS to_TO the_DT financial_JJ statements_NNS ._.
The_DT Directors_NNS are_VBP required_VBN to_TO prepare_VB the_DT financial_JJ statements_NNS on_IN a_DT going_VBG concern_NN basis_NN unless_IN it_PRP is_VBZ inappropriate_JJ to_TO presume_VB that_IN the_DT Group_NNP and_CC the_DT Company_NN will_MD continue_VB in_IN business_NN ._.
The_DT Directors_NNS are_VBP responsible_JJ for_IN ensuring_VBG proper_JJ accounting_NN records_NNS are_VBP kept_VBN which_WDT disclose_VBP with_IN reasonable_JJ accuracy_NN at_IN any_DT time_NN the_DT financial_JJ position_NN of_IN the_DT Company_NN and_CC enable_VB them_PRP to_TO ensure_VB that_IN the_DT financial_JJ statements_NNS comply_VBP with_IN the_DT Companies_NNS Act_NNP 1985_CD ._.
They_PRP are_VBP also_RB responsible_JJ for_IN taking_VBG reasonable_JJ steps_NNS to_TO safeguard_VB the_DT assets_NNS of_IN the_DT Group_NNP and_CC the_DT Company_NN and_CC prevent_VB and_CC detect_VB fraud_NN and_CC other_JJ irregularities_NNS ._.
Basis_NN of_IN Consolidation_NN and_CC Presentation_NN of_IN Financial_NNP Information_NNP The_NNP preparation_NN of_IN the_DT Financial_NNP Statements_NNP in_IN conformity_NN with_IN generally_RB accepted_VBN accounting_NN principles_NNS requires_VBZ management_NN to_TO make_VB estimates_NNS and_CC assumptions_NNS that_WDT affect_VBP the_DT reported_VBN amounts_NNS of_IN assets_NNS and_CC liabilities_NNS and_CC disclosure_NN of_IN contingent_JJ assets_NNS and_CC liabilities_NNS at_IN the_DT date_NN of_IN the_DT Financial_NNP Statements_NNP and_CC the_DT reported_VBN amounts_NNS of_IN revenues_NNS and_CC expenses_NNS during_IN the_DT reporting_NN period_NN ._.
Actual_JJ results_NNS could_MD differ_VB from_IN those_DT estimates_NNS ._.
AstraZeneca_NNP has_VBZ adopted_VBN the_DT provisions_NNS of_IN UITF_NNP 38_CD Accounting_NN for_IN ESOP_NNP Trusts_NNPS in_IN the_DT current_JJ year_NN ._.
There_EX was_VBD no_DT effect_NN on_IN results_NNS and_CC the_DT effect_NN on_IN net_JJ assets_NNS was_VBD not_RB significant_JJ ._.
